ROR1 and B-cell chronic lymphocytic leukemia: Owing to the importance of survival signals provided by the ROR1 pathway to CLL cells, cirmtuzumab, a humanized IgG1 mAb with a high affinity and specificity for ROR1, was generated to block this signal [99] (Fig. 2).